India’s Pharmacy Protest: Why Traditional Chemists Are Fighting E‑Pharmacies

When you stroll down a typical Indian street, the smell of antiseptic and the chatter of local chemists have been part of the daily soundtrack for generations. Yet, in the past few months that familiar scene has been punctuated by an unexpected sight: shop owners hanging signs that read ‘Closed’ and, in some cases, whole rows of pharmacies shuttered overnight. The cause? A coordinated strike by traditional chemists who feel squeezed out by the rapid growth of e‑pharmacies.

It isn’t just a dispute over who sells the next bottle of paracetamol. For many chemists, the protest is deeply personal. “My family has run this shop for 30 years,” says Rajesh Kumar, a 55‑year‑old proprietor in Lucknow. “Now a new app can deliver the same medicines to my doorstep customers, and I’m left wondering if there’s any future for us.” Those words echo a sentiment felt in Mumbai, Delhi, Chennai and countless smaller towns where the physical pharmacy has long been a trusted community hub.

The rise of e‑pharmacies in India has been meteoric. Since 2017, platforms like NetMeds, 1mg, and PharmEasy have claimed a sizable slice of the market, buoyed by aggressive advertising, convenient home delivery, and, not least, the COVID‑19 pandemic that made people wary of stepping out for even routine prescriptions. While these services tout safety and convenience, critics argue that the regulatory framework governing them is still in its infancy.

One of the core complaints from striking chemists revolves around the lack of a robust licensing system for online sellers. Unlike a brick‑and‑mortar store that must display a valid drug licence, many e‑pharmacies operate with what some describe as a “gray‑area” permit. “We have to follow strict guidelines—store audits, temperature controls, verified pharmacists on site,” explains Dr. Sunita Rao, a pharmacist turned activist. “When a startup can bypass many of these checks, it raises real concerns about drug quality and patient safety.”

Adding fuel to the fire is the perception that e‑pharmacies undermine pricing norms. Traditional chemists claim that online platforms engage in price wars, often selling medicines at rates that are unsustainable for small retailers. “A 500‑ml bottle of cough syrup that used to cost Rs. 120 now shows up for Rs. 90 online,” notes Kumar. “We simply can’t match that without compromising on profit.” The resultant price disparity, they argue, could push many family‑run shops out of business, eroding local employment and community ties.

It’s not just economics. There’s also a palpable fear about counterfeit drugs slipping through the digital supply chain. While the government has launched the “E‑Pharmacy Registration” portal to bring online sellers under a unified regulatory umbrella, enforcement remains patchy. In a few reported cases, customers received medicines that were either expired or not the brand advertised, sparking alarm among health‑conscious citizens.

The strike, which began in early May, has seen over 2,000 chemist unions across 12 states suspend operations for a day, followed by staggered closures in subsequent weeks. The aim is twofold: to press the Ministry of Health for stricter licensing norms for e‑pharmacies, and to demand a level playing field that protects traditional retailers.

Government response so far has been a mix of acknowledgment and caution. Health Minister Harsh Vardhan, in a recent press briefing, said the ministry is “reviewing existing policies to ensure that patient safety is never compromised.” Yet, he also emphasized the need to “embrace digital innovation” to reach remote populations. This dual stance leaves many chemists frustrated, feeling that their concerns are being heard but not yet acted upon.

Meanwhile, e‑pharmacies argue that they are simply filling a market gap, especially in rural and underserved areas where physical pharmacies are scarce. A spokesperson for PharmEasy highlighted that their platform has delivered over 1.5 million prescriptions to patients in Tier‑2 and Tier‑3 cities, improving access to essential medicines. “We are not looking to replace chemists,” the spokesperson said, “but to complement them.”

So, where does this leave the average consumer? For now, many Indians are caught in a tug‑of‑war between convenience and trust. Some continue to rely on their neighborhood chemist, valuing the personal advice that comes with a face‑to‑face interaction. Others, pressed by time or mobility constraints, are gradually shifting to the ease of a few clicks and a doorstep delivery.

What is clear is that the debate is far from over. As the digital health ecosystem evolves, regulators will need to craft policies that protect public health, ensure fair competition, and preserve the livelihoods of millions of chemists who have been the backbone of Indian healthcare for decades. Until then, the streets of India will likely echo with the occasional sign that reads, ‘Closed for now, but we’ll be back.’